Fundz

Watching Twist Bioscience Corporation? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Twist Bioscience Corporation

www.twistbioscience.com
Filed: Aug 4, 2026South San FranciscoCIK: 0001581280Biotechnology
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Twist Bioscience Corporation completed a public offering of 3,125,000 shares at $96.00 per share, raising $300 million to fund expansion and ongoing projects. The underwriters exercised their option to purchase an additional 468,750 shares, demonstrating strong investor demand.

Key Takeaways

Twist Bioscience raised $300 million through a public offering of common stock at $96.00 per share

The underwriting syndicate (Goldman Sachs, William Blair, Leerink Partners, Guggenheim Securities) exercised their 30-day option to purchase 468,750 additional shares on August 5, 2026

2 more takeaways

Related Filings (1)

1 more filing from Twist Bioscience Corporation in the last 90 days

Filing Overview

Form Type8-K
Filing DateAug 4, 2026
Item1.01
CategoryMaterial Agreement
CIK0001581280
Accession #001-38720
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offering

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings

Twist Bioscience Corporation filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.